Pomalidomide (CC-4047)

For research use only. Not for use in humans.

目录号:S1567 中文名称:泊马度胺

Pomalidomide (CC-4047) Chemical Structure

CAS No. 19171-19-8

Pomalidomide (CC-4047)抑制LPS诱导的TNF-α释放,在PBMCs中IC50为13 nM。Pomalidomide 可以在PROTAC中用作靶向 E3 ligase 和抑制 E3 ligase protein cereblon (CRBN)。Pomalidomide可促进凋亡和细胞周期阻滞。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 748.13 现货
RMB 576.14 现货
RMB 3029.87 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Pomalidomide (CC-4047)发表文献80篇:

产品安全说明书

E3 ligase Ligand抑制剂选择性比较

生物活性

产品描述 Pomalidomide (CC-4047)抑制LPS诱导的TNF-α释放,在PBMCs中IC50为13 nM。Pomalidomide 可以在PROTAC中用作靶向 E3 ligase 和抑制 E3 ligase protein cereblon (CRBN)。Pomalidomide可促进凋亡和细胞周期阻滞。
特性 Pomalidomide是Thalidomide 衍生物,效果比Thalidomide强10,000倍。
靶点
CRBN [5]
()
TNF-α [1]
(PBMCs)
13 nM
体外研究

Pomalidomide 抑制脂多糖(LPS)刺激的TNF-alpha释放,作用于人类 PBMC 和人类全部血液时,IC50分别为13 nM 和25 nM。[1] Pomalidomide抑制 IL-2刺激的T 调节细胞,IC50为~1 μM。[2]6.4 nM-10 μM Pomalidomide 处理人类外周血T细胞 ,提高 IL-2 产量,作用于CD4+子集比作用于CD8+子集有效。 Pomalidomide 比CC-5013显著促进IL-2, IL-5,和 IL-10, 比CC-5013稍微促进 IFN-γ。Pomalidomide 作用于Jurkat细胞,增强 SEE和 Raji细胞诱导的 AP-1 转录活性,1 μM时最高增强4倍,这种作用存在剂量依赖性。[3] 用不同浓度Pomalidomide(2.5-40 μg/mL) 处理Raji细胞48小时,导致细胞增殖和DNA合成明显降低,与对照组相比降低~40% 。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 MUnDfZRwfG:6aXPpeJkhSXO|YYm= MYmxNEDPxE1? MX6yOEBp M{TQWpBwfGWwdHz5JIF2\22nboTzJIRqemWldDDhcoQhcW6maYLlZ5QhVU1iY3XscEBscWyuaX7nJIJ6KFODUh?= MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|M{iyO|MoRjJ4M{O4Nlc{RC:jPh?=
J-CD38 NVvZ[2l{S3m2b4TvfIlkcXS7IFHzd4F6 NVfvfmtbOTBizszN MkS4NlQhcA>? NIr3WI5xd3SnboTsfUBifWevZX70d{BlcXKnY4SgZY5lKGmwZHny[YN1KE2PIHPlcIwhc2mubHnu[{BjgSCVQWK= MnvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|M{iyO|MoRjJ4M{O4Nlc{RC:jPh?=
R-CD38 NFjqPXFEgXSxdH;4bYNqfHliQYPzZZk> NEPOU4wyOCEQvF2= MX2yOEBp NEmwPGJxd3SnboTsfUBifWevZX70d{BlcXKnY4SgZY5lKGmwZHny[YN1KE2PIHPlcIwhc2mubHnu[{BjgSCVQWK= NFvHeHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPFI4Oyd-Mk[zN|gzPzN:L3G+
BC-3 NX3IWWU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLxN|kuOTJ3MDDuUS=> M{T3OFUh\A>? NITwb3pFVVORwrC= MkLETWM2OD1zMEegcm0tKGmwaHnibZR{KGOnbHygTWM2OD1zMEegcm0tKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NWT0e2M5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
BCBL-1 NFvBVHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nKOVM6NTF{NUCgcm0> MkXIOUBl Mn\jSG1UV8Li MVXJR|UxRTd2IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MoHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
JSC-1 NUPZeW43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLmZpJOOzlvMUK1NEBvVQ>? MXG1JIQ> M1\NWWROW00EoB?= Mm\zTWM2OD1|NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NUKwb21KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
VG-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\JelM6NTF{NUCgcm0> M1\wTFUh\A>? MlraSG1UV8Li NF\seZNKSzVyPUGwNUBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NXeyc|MxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
UMPEL-1 NEHKfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnUeYtlOzlvMUK1NEBvVQ>? NXLtSYE2PSCm M4nsO2ROW00EoB?= NHzyXZNKSzVyPUOyJI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 M3vyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
UMPEL-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rEcVM6NTF{NUCgcm0> M164[|Uh\A>? Ml7ZSG1UV8Li MV;JR|UxRTFzMTDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
BC-1 M4mwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHtU4o{QS1zMkWwJI5O M3v5UVUh\A>? NV3idG06TE2VT9Mg NFfrfmdKSzVyPUe0OEBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> NFuzXJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
BCP-1 M3jPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;3N|kuOTJ3MDDuUS=> NVm1dXNLPSCm NUDvZpBYTE2VT9Mg NYDOU5pkUUN3ME2zPVYhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MomzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUm5N|koRjJ4MUG5PVM6RC:jPh?=
APK-1 M1L1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHtWGFuOzlvMUK1NEBvVQ>? M2[5SlUh\A>? NYj0fnd7TE2VT9Mg M4e2cWlEPTB;MkK2JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
RPMI8226  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn2c5FXOC5yMT21NEDPxE1? MXm0PEBp NX7TR|VCTE2VT9Mg NGe2ZlJKSzVyPUig{txO M3fhNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm3PFczLz5{NkC5O|g4OjxxYU6=
OPM2  NV:zXG04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLTcG4xNjBzLUWwJO69VQ>? NXPDSYlMPDhiaB?= NIDxOIRFVVORwrC= M17qfWlEPTB;MUCg{txO NH\sc3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
RPMI8226  MUPGeY5kfGmxbjDBd5NigQ>? NEGzNYgyOCEQvF2= NVf4Vm5{PDhiaB?= NFPSd4FFVVORwrC= M{H3fZN1emWwZ4To[Y5{KGO7dH;wcIF{dWmlLX71Z4xm[XJic3j1eJRtcW6pIH;mJI1VV1JiYX7kJJAudVSRUjDwdo91\Wmw NGe4VnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
OPM2  M17YfmZ2dmO2aX;uJGF{e2G7 M13teFExKM7:TR?= M{nlVlQ5KGh? MoC1SG1UV8Li MmTEd5Rz\W6pdHjlcpMh[3m2b4DsZZNucWNvboXjcIVieiC|aIX0eIxqdmdib3[gcXRQWiCjbnSgdE1uXE:UIIDyc5RmcW5? Mk\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUe4O|IoRjJ4MEm3PFczRC:jPh?=
RPMI8226 Ml;xSpVv[3Srb36gRZN{[Xl? NYjJeG9IOC5zLUGwJO69VQ>? MmnGOEBp NEDrdHBFVVORwrC= MkPlbY5kemWjc3XzJHZGT0ZibWLORUBmgHC{ZYPzbY9v M2DjTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPVkxLz5{NUC1N|k6ODxxYU6=
SH-SY5Y  M4e0[GFxd3C2b4Ppd{BCe3OjeR?= MoPRNlXDqM7:Zz;tUC=> NGXrRXMyyqCq NFH3ZlNk[XW|ZYOgd5RifGm|dHnjZYxtgSC|aXfubYZq[2GwdDDy[YR2[3Srb36gbY4h[m:2aDDDVGYuKGGwZDDDVGYsS01vaX7keYNm\CCjcH;weI9{cXQEoB?= MmTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{WyO|YoRjJ2OUe1Nlc3RC:jPh?=
JJN3 M{PuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3FcJBnOC5zLUGwNEDPxE1? NHvzTng4OiCq NXy5XnB7TE2VTx?= M2fyNYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NWPmTGM4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxO|g{PzhpPkKzNVc5Ozd6PD;hQi=>
XG-1 NH7iU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\uOolFOC5zLUGwNEDPxE1? M4DsPFczKGh? MYHEUXNQ MVrpcohq[mm2czDj[YxtKGe{b4f0bC=> MlHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzN{izO|goRjJ|MUe4N|c5RC:jPh?=
CD138+  NVLJO|BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjsRodZOC5zLUGwNEDPxE1? NE\PTGw4OiCq MnjBSG1UVw>? NGHYNVlqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NIfrbVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G3PFM4QCd-MkOxO|g{Pzh:L3G+
XG-1 M3HkPGZ2dmO2aX;uJGF{e2G7 MX6yM|ExOCEQvF2= M4fKXVI1KGh? MWrEUXNQ M1XQR4lvcGmkaYTzJGNEVDNxTVnQMVHPuSCvUl7BJIV5eHKnc4Ppc44> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF5OEO3PEc,OjNzN{izO|g9N2F-
U266 NVzzcYgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjS[|ExNjBzLUGwJO69VQ>? NV;iZpJVPDkkgJno MoKwSG1UVw>? MlPnbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYLQTYU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OVIxODhpPkKyOVUzODB6PD;hQi=>
CRBN60 NGnISI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECxZ2UxNjBzLUGwJO69VQ>? NVfRNmUzPDkkgJno MWDEUXNQ M1HyOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXLLWZh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OVIxODhpPkKyOVUzODB6PD;hQi=>
CRNB75 M{Plc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv0NE4xOS1zMDFOwG0> MmPWOFjjiImq M{DYTWROW09? NYjZcFdjcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? M{TFVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWyNFA5Lz5{MkW1NlAxQDxxYU6=
MM.1S MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;DWGdsOC5yMT2xNEDPxE1? MlTwOFjjiImq M{PWWWROW09? NFXmblZ{cWewaX\pZ4FvfGy7IHnubIljcXS|IIDyc4xq\mW{YYTpc44h[XRiY3;uZ4VvfHKjdHnvcpMh[XNibH;3JIF{KDBwMEJOwG0> M{O5PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
OPM2 NF:0SppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPNNE4xOS1zMDFOwG0> MXe0PQKBkWh? NXWxS4hLTE2VTx?= MX\zbYdvcW[rY3HueIx6KGmwaHnibZR{KHC{b3zp[oVz[XSrb36gZZQh[2:wY3XueJJifGmxboOgZZMhdG:5IHHzJFAvODIQvF2= M1rGXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
MM.1S MkjXSpVv[3Srb36gRZN{[Xl? M1;NV|ExKM7:TR?= NHLHSXg4OiCq MYDEUXNQ NF7XXVZ{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA> MmrxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
H929 M4G2Z2Z2dmO2aX;uJGF{e2G7 NX7FTFFkOTBizszN M1X6dVczKGh? M{DOPGROW09? NH\ZRlN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUheHKxdHXpckBt\X[nbDDv[kBEN0WEUN8yJIl{d2[xcn3zxsA> M1LIZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
OPM2 NIXQW|RHfW6ldHnvckBCe3OjeR?= NVn5UWRWOTBizszN NXjrZYRWPzJiaB?= MnPmSG1UVw>? MWTzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgdJJwfGWrbjDs[ZZmdCCxZjDDM2VDWM7{IHnzc4Zwem2|wrC= MlL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
CT26 NUOwXIozTnWwY4Tpc44hSXO|YYm= NV;6fXR3OS9zMDFOwG0> NHfNcW0zPCCq NEjMcotz\WS3Y3XzJJRp\SCwdX3i[ZJ{KG:oIHzpeoUh[2:ub37p[ZPDqA>? NIjOSIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zPFk4Pyd-MUm2N|g6Pzd:L3G+
T-cells M1nvVmZ2dmO2aX;uJIF{e2G7 NXvIWZZqOiC2bzCzJIRigXN? M1H0N2lvcGmkaYTpc44hd2ZiSVytNkBxem:mdXP0bY9vKGmwIHj1cYFvKFRiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgNkB1dyB|IHThfZMh[nliRVzJV2EtKEWFNUCgQUAxNjByODFOwG0v M1f2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MU[4NFE6Lz5{M{G2PFAyQTxxYU6=
DF15 NFfQU25HfW6ldHnvckBie3OjeR?= NXfBd3hrPCCqcoO= NEjuboxKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BmWExvdHHn[4VlKGGrb3zvd{Bi\nSncjC0JIhzeyCkeTDseY1qdm:vZYTybYMh[W6jbInzbZMtKEWFNUCgQUAxNjB{MjFOwG0v NGXS[GE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOVczOCd-Mki0NlU4OjB:L3G+
DF15 MlTRSpVv[3Srb36gZZN{[Xl? M{XLZlQhcHK| MULJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDlVGwufGGpZ3XkJIls[XKxczDh[pRmeiB2IHjyd{BjgSCudX3pco9u\XS{aXOgZY5idHm|aYOsJGVEPTBiPTCwMlAzPCEQvF2u MnW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
DF15 M{CwU2Z2dmO2aX;uJIF{e2G7 MkWzOEBpenN? M{D6Nmlv\HWldHnvckBw\iCFUly0M2NTSk5idXLpdZVqfGmwIHzp[4F{\S2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDlfJBz\XO|aX7nJJBNV0NvZWDMMZRi\2enZDDhbY9td3NiYX\0[ZIhPCCqcoOgZpkhdHWvaX7ld4NmdmOnIHLhd4VlKGKndHGt[4Ft[WO2b4Pp[IF{\SCnbor5cYUh\nKjZ33lcpRifGmxbjDjc41xdGWvZX70ZZRqd25iYYPzZZktKEWFNUCgQUAxNjB{NzFOwG0v NYjIfXRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVg2ODdpPkK4N|U5PTB5PD;hQi=>
NAMALWA MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MVG3NkBpenN? MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6DTVHMW2Eh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDbN2hefGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUCgQUAxNjB|IN88UU4> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4OECxPUc,OjNzNkiwNVk9N2F-
HeLa M1\rc2Z2dmO2aX;uJIF{e2G7 NXzHXpdOUW6qaXLpeIlwdiCxZjDJUE0yNWGucHjhMYlv\HWlZXSgUmYuc2GycHHCJIFkfGm4YYTpc44hcW5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{BjdG:la3nu[{Bw\iCyNUCvdFY2KG63Y3zlZZIhfHKjboPsc4NifGmxbjygTWM2OCB;IEGuNlch|ryPLh?= M3PHWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OES1PFUxLz5zN{i0OVg2ODxxYU6=
DF15 MVXGeY5kfGmxbjDhd5NigQ>? MmDHNE4xOSC2bzCxJJVO MY[1JIhzew>? MVLJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQh[WmxbH;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiYYSgNE4xOSC2bzCxJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> M33KO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK1O|IxLz5{OESyOVczODxxYU6=
OPM2 MW\GeY5kfGmxbjDhd5NigQ>? NGjqWZYxNjBzIITvJFEhfU1? MVy1JIhzew>? MkiyTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGmtYYLvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCRUF2yJINmdGy|IHH0JFAvODFidH:gNUB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
DF15 MoL3SpVv[3Srb36gZZN{[Xl? M2PIS|AvODFidH:gNUB2VQ>? MWW1JIhzew>? M2TBR2lv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCra3Hyc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDheEAxNjBzIITvJFEhfU1iYX\0[ZIhPSCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? NWTaSppYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
OPM2 NID1NI1HfW6ldHnvckBie3OjeR?= MV6wMlAyKHSxIEGgeW0> MnG3OUBpenN? NYnrbppDUW6mdXP0bY9vKG:oIHPldoVjdG:wLX3l[IlifGWmIHHpc4xweyCmZXfyZYRifGmxbjDpckBpfW2jbjDPVG0zKGOnbHzzJIF1KDBwMEGgeI8hOSC3TTDh[pRmeiB3IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m| NYPlelczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘瘿뾠ՂᾰƌՂĀ㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘

29496670
体内研究

Pomalidomide 作用于SCID小鼠,增强 Rituximab作用于B细胞淋巴瘤的抗癌效果。Pomalidomide和Rituximab联用使鼠平均寿命为74天,与 CC5013/Rituximab 处理的鼠平均寿命为58天。NK细胞耗尽则Pomalidomide和Rituximab协同作用完全被废除, 说明NK细胞增多是Pomalidomide增强 Rituximab抗癌的一个机制。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

抑制TNF-α合成实验 :

在内毒素(LPS)刺激的PBMC中测定TNF-α抑制活性。Pomalidomide 加到PBMCs中1小时,然后加入LPS (1 μg/mL),再处理18-20小时。收集悬浮液,通过ELISA测定悬浮液中的TNF-α浓度。通过回归曲线分析计算IC50值。人类全部血液TNF抑制实验和PBMC实验差不多,除了肝素化的新鲜血液直接加到微量滴定法板上。
细胞实验:

[4]

- 合并
  • Cell lines: Raji,SU-DHL-4和SU-DHL-10 细胞系
  • Concentrations: 溶于DMSO, 终浓度为2.5-40 μg/mL
  • Incubation Time: 24或48小时
  • Method:

    为了测定细胞凋亡,用Pomalidomide(5 μg/mL)处理淋巴瘤细胞系24小时或48小时。用FITC标记的膜联蛋白V和碘化丙啶进行细胞染色。使用荧光激活细胞分选仪/FACStar 和流式细胞仪,通过多色流式细胞仪分析细胞凋亡。如果膜联蛋白V阳性及碘化丙啶阴性/阳性,则判断为细胞凋亡(分布为凋亡早期和晚期)。为了测定细胞增殖,用Pomalidomide(2.5, 5, 10, 20,和40 μg/mL)处理淋巴瘤细胞系24小时或48小时。在96孔板上,每孔加入1 μCi[3H]-胸甘,细胞再温育18小时。收集细胞,加到96孔玻璃过滤器中,然后使用自动闪烁计数器测定摄取的[3H]-胸甘。


    (Only for Reference)
动物实验:

[4]

- 合并
  • Animal Models: 携带扩散性淋巴瘤的SCID小鼠
  • Dosages: 0.5 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 273.24
化学式

C13H11N3O4

CAS号 19171-19-8
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04902443 Recruiting Drug: Pomalidomide|Drug: Nivolumab Viral Associated Malignancies|Kaposi Sarcoma|EBV/KSHV-associated Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 7 2021 Phase 1
NCT04577755 Recruiting Drug: Pomalidomide Skin Kaposi Sarcoma National Cancer Institute (NCI) July 1 2021 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • 回答:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • 问题 2:

    I would like to know if the pomalidomide is racemic or optically active?

  • 回答:

    Our S1567 Pomalidomide is racemic.

免费分装抑制剂

E3 ligase Ligand Inhibitors with Unique Features

Tags: 购买Pomalidomide (CC-4047) | Pomalidomide (CC-4047)供应商 | 采购Pomalidomide (CC-4047) | Pomalidomide (CC-4047)价格 | Pomalidomide (CC-4047)生产 | 订购Pomalidomide (CC-4047) | Pomalidomide (CC-4047)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID